Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia

There is great interest in identifying a glucagon-like peptide-1 (GLP-1)–based combination therapy that will more effectively promote weight loss in patients with type 2 diabetes. Fibroblast growth factor 21 (FGF21) is a compelling yet previously unexplored drug candidate to combine with GLP-1 due t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Adv
Main Authors: Gilroy, C. A., Capozzi, M. E., Varanko, A. K., Tong, J., D'Alessio, D. A., Campbell, J. E., Chilkoti, A.
Format: Artigo
Jezik:Inglês
Izdano: American Association for the Advancement of Science 2020
Teme:
Research Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449677/
https://ncbi.nlm.nih.gov/pubmed/32923621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aaz9890
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki